Search Results

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference being held from May 17-22, 2024 in San Diego, California.

RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).

Foresee Pharmaceuticals announced that it will actively participate in and present two posters at the 2024 American Thoracic Society International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.

Vicore Pharma Holding AB announced multiple presentations at the 2024 American Thoracic Society International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis.

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.

ASLAN Pharmaceuticals announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society International Conference 2024 in San Diego, California.

ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024.